Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 51
Filter
1.
Rev. Hosp. Ital. B. Aires (2004) ; 41(1): 26-30, mar. 2021. ilus
Article in Spanish | LILACS | ID: biblio-1178336

ABSTRACT

El pioderma gangrenoso ampollar es una variedad infrecuente de pioderma gangrenoso, que se asocia en el 50-70% de los casos con trastornos oncohematológicos. Se comunica el caso de una paciente de 59 años, que consultó por fiebre y ampollas purpúricas de rápida progresión, con compromiso cutáneo mucoso. Con sospecha de una enfermedad neutrofílica, ampollar, o infección por gérmenes oportunistas, se realizó biopsia de piel para estudio histopatológico, inmunofluorescencia directa y cultivo. Los cultivos y la inmunofluorescencia directa fueron negativos, y la anatomía patológica reveló un denso infiltrado inflamatorio con predominio neutrofílico en dermis. Ante el diagnóstico de pioderma gangrenoso ampollar, se realizó una punción-aspiración de médula ósea cuyo resultado fue compatible con leucemia mieloide aguda. Se instauró tratamiento con corticosteroides sistémicos, a pesar de lo cual la paciente evolucionó desfavorablemente y falleció a los 15 días de su ingreso hospitalario. Este caso ilustra la asociación de esta enfermedad cutánea con trastornos oncohematológicos y el mal pronóstico que esto implica a corto plazo. (AU)


Bullous pyoderma gangrenosum is an infrequent type of pyoderma gangrenosum, associated with onco hematological diseases in 50-70% of cases. We present the case of a 59-year-old patient with fever and mucocutaneous hemorrhagic bullous of rapid progression. A biopsy for histopathology, direct immunofluorescence (DIF) and skin culture was made, considering the possibility of neutrophilic dermatoses, bullous dermatosis or an opportunistic infection. The results of both the culture and the DIF were negative. The histopathological examination of the specimen revealed a dense dermal polymorphic infiltrate composed primarily of neutrophils. Considering bullous pyoderma gangrenosum as a potential diagnosis, a bone-marrow biopsy was performed. This study revealed an acute myeloid leukemia. Although systemic corticosteroid therapy was begun, the patient presented an unfavorable evolution that led to her death 15 days after her admission at the hospital. This case shows the association between bullous pyoderma gangrenosum and onco hematological diseases. In addition, it highlights the poor prognosis related to these diseases in the short term. (AU)


Subject(s)
Humans , Female , Middle Aged , Leukemia, Myeloid, Acute/pathology , Pyoderma Gangrenosum/diagnosis , Paraneoplastic Syndromes/pathology , Respiration, Artificial , Azacitidine/therapeutic use , Myelodysplastic Syndromes/pathology , Acyclovir/administration & dosage , Methylprednisolone/administration & dosage , Vancomycin/administration & dosage , Cardiotonic Agents/therapeutic use , Ceftazidime/administration & dosage , Amphotericin B/administration & dosage , Imipenem/administration & dosage , Sweet Syndrome/etiology , Pyoderma Gangrenosum/etiology , Pyoderma Gangrenosum/pathology , Pyoderma Gangrenosum/drug therapy , Adrenal Cortex Hormones/therapeutic use , Meropenem/administration & dosage
2.
Autops. Case Rep ; 11: e2021339, 2021. tab, graf
Article in English | LILACS | ID: biblio-1345358

ABSTRACT

Myeloid sarcoma (MS) is a rare extramedullary neoplasm of myeloid cells, which can arise before, concurrently with, or following hematolymphoid malignancies. We report 04 such cases of MS, diagnosed in this institute over a period of 6 years, during various phases of their respective myeloid neoplasms/leukemias. These cases include MS occurring as a relapse of AML (Case 1), MS occurring as an initial presentation of CML (Case 2), MS occurring during ongoing chemotherapy in APML (Case 3), and MS presenting as a progression of MDS to AML (Case 4). In the absence of relevant clinical history and unemployment of appropriate immunohistochemical (IHC) studies, these cases have a high risk of being frequently misdiagnosed either as Non-Hodgkin's Lymphoma (NHL) or small round cell tumors or undifferentiated carcinomas, which may further delay their management, making an already bad prognosis worse. This case series has been designed to throw light on the varied presentation of MS and the lineage differentiation of its neoplastic cells through the application of relevant IHC markers along with their clinical correlation.


Subject(s)
Humans , Male , Female , Child, Preschool , Adolescent , Middle Aged , Aged , Sarcoma, Myeloid/pathology , Myelodysplastic Syndromes/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Leukemia, Myeloid, Acute/pathology , Leukemia, Promyelocytic, Acute/pathology , Diagnostic Errors/prevention & control
4.
Rev. peru. med. exp. salud publica ; 36(2): 353-359, abr.-jun. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1020795

ABSTRACT

RESUMEN La neoplasia blástica de células dendríticas plasmocitoides (NBCDP) es una malignidad hematológica poco frecuente y generalmente agresiva, por lo cual se requiere su reconocimiento precoz. A continuación, se describe el curso clínico prolongado de un paciente masculino de 60 años con NBCDP procedente de Venezuela, en cuyos hallazgos más relevantes destacó la presencia de lesiones cutáneas, organomegalias, infiltración de la médula ósea y del sistema nervioso central. Posterior al diagnóstico se indicó quimioterapia sistémica, no obstante, el paciente falleció por complicaciones respiratorias durante la fase de inducción del tratamiento. En esta enfermedad es necesario establecer el diagnóstico diferencial con trastornos linfoproliferativos, leucemias linfoides y mieloides agudas, constituyendo el análisis morfológico de las células neoplásicas un aspecto importante para una adecuada orientación diagnóstica.


ABSTRACT Blastic plasmacytoid dendritic cell blast neoplasm (BPDCN) is a rare and generally aggressive hematologic malignancy, requiring early recognition. Below is a description of the prolonged clinical course of a 60-year-old male patient with BPDCN from Venezuela, whose most relevant findings highlighted the presence of skin lesions, organomegaly, infiltration of the bone marrow and central nervous system. Systemic chemotherapy was prescribed after diagnosis; however, the patient died of respiratory complications during the induction phase of treatment. In this disease, it is necessary to establish the differential diagnosis with lymphoproliferative disorders, acute lymphoid and myeloid leukemias. The morphological analysis of neoplastic cells is, thus, an important aspect toward proper diagnostic guidance.


Subject(s)
Humans , Male , Middle Aged , Skin Neoplasms/diagnosis , Dendritic Cells/pathology , Leukemia, Myeloid, Acute/diagnosis , Skin Neoplasms/pathology , Leukemia, Myeloid, Acute/pathology , Diagnosis, Differential , Lymphoproliferative Disorders/diagnosis
5.
Rev. chil. obstet. ginecol. (En línea) ; 84(4): 332-336, 2019. graf, ilus
Article in Spanish | LILACS | ID: biblio-1058156

ABSTRACT

RESUMEN Introducción y objetivos: El sarcoma mieloide puede ser la primera manifestación de la leucemia mieloide aguda (LMA), presentarse simultáneamente o constituir una forma de recaída. Material y métodos: Presentamos el caso de una paciente con sarcoma mieloide uterino, como forma de recaída de LMA. Resultados: El diagnóstico se basa en los hallazgos histopatológicos, la inmunohistoquímica y el inmunofenotipo. El tratamiento y el pronóstico son similares a LMA. Conclusión: La afectación uterina por leucemia mieloide extramedular es rara pero debe tenerse en cuenta en el diagnostico diferencial de una masa uterina en aquellas pacientes con antecedentes de LMA.


ABSTRACT Introduction and objectives: Myeloid Sarcoma can present as a first MLA sign, concurrently with or at relapse form. Materials and methods: We present the case of a patient with uterine myeloid sarcoma, as a form of relapse of MLA. Results: The diagnostic is based on the histopathology findings along with immunohistochemistry and immunophenotyping. Conclusion: Uterine involvement due to extramedullary myeloid leukemia is rare but it should be taken into account in the differential diagnosis of a uterine mass in those patients with a history of MLA.


Subject(s)
Humans , Female , Aged , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/therapy , Sarcoma, Myeloid/diagnostic imaging , Thrombosis , Immunohistochemistry , Magnetic Resonance Spectroscopy , Leukemia, Myeloid, Acute/pathology
6.
Biol. Res ; 52: 11, 2019. graf
Article in English | LILACS | ID: biblio-1011413

ABSTRACT

BACKGROUND: The present study aimed to investigate the underlying role of interferon-regulatory factor 2 (IRF2)-inositol polyphosphate-4-phosphatase, type-II (INPP4B) axis in the regulation of autophagy in acute myeloid leukemia (AML) cells. METHODS: Quantitative real time PCR (QRT-PCR) and western blot were performed to determine the expression levels of IRF2, INPP4B and autophagy-related markers in AML cell lines. Autophagy was assessed by elevated Beclin-1 expression, the conversion of light chain 3 (LC3)-I to LC3-II, downregulated p62 expression and green fluorescent protein (GFP)-LC3 puncta formation. The colony formation and apoptosis assays were performed to determine the effects of IRF2 and INPP4B on the growth of AML cells. RESULTS: IRF2 and INPP4B were highly expressed in AML cell lines, and were positively correlated with autophagy-related proteins. Overexpression of IRF2 or INPP4B stimulated autophagy of AML cells, whereas inhibition of IRF2 or INPP4B resulted in the attenuation of autophagy. More importantly, IRF2 or INPP4B overexpression reversed autophagy inhibitor, 3-methyladenine (3-MA)-induced proliferation-inhibitory and pro-apoptotic effects, while IRF2 or INPP4B silencing overturned the proliferation-promoting and anti-apoptotic effects of autophagy activator rapamycin. CONCLUSION: IRF2-INPP4B signaling axis attenuated apoptosis through induction of autophagy in AML cells.


Subject(s)
Humans , Autophagy , Leukemia, Myeloid, Acute/metabolism , Apoptosis , Phosphoric Monoester Hydrolases/metabolism , Interferon Regulatory Factor-2/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Leukemia, Myeloid, Acute/pathology , Signal Transduction , Blotting, Western , Fluorescent Antibody Technique , Cell Line, Tumor , Cell Proliferation , Real-Time Polymerase Chain Reaction
7.
Bol. méd. Hosp. Infant. Méx ; 74(2): 122-133, mar.-abr. 2017. tab
Article in Spanish | LILACS | ID: biblio-888605

ABSTRACT

Resumen: Introducción: Se desconocen las características citopatológicas de las leucemias agudas en pacientes de Chiapas, México, ya que es una población relativamente aislada con alto índice de consanguinidad, lo cual podría afectar la evolución y la respuesta terapéutica. Métodos: Se clasificaron morfológica, inmunofenotípica y genotípicamente 81 casos de leucemia aguda en pacientes atendidos en el Hospital de Especialidades Pediátricas de Chiapas, indicando riesgo al ingreso y situación al momento del estudio. Los resultados se comparan con información nacional e internacional pertinente. Resultados: Se encontró la siguiente proporción de tipos de leucemia aguda: leucemias B, 75.3%; mieloides, 16%; de células T, 3.7%; B-M, 3.7% y de células NK, 1.2%. Las alteraciones genéticas estuvieron presentes en 40.6% de las B y en 69% de las mieloides. La alteración genética se relacionó con la evolución del paciente a corto plazo en las leucemias tipo B; no así en las mieloides. En las B, los casos con el gen MLL alterado fallecieron en menos de un mes, los casos con la translocación t(1;19)(q23;p13) han tenido buena evolución, y aquellos con la t(12;21)(p13;q22) han tenido mala evolución a medio plazo. La hiperdiploidía se presentó en el 20% de los casos B; el 83% de ellos permanecen en remisión de 1 a 12 meses desde el diagnóstico. El 69% de los casos con leucemias mieloides falleció o abandonó el tratamiento en recaída de 15 días a 37 meses del diagnóstico. Conclusiones: La proporción de los diferentes tipos de leucemia aguda atendidas en el HEP es similar a la encontrada en otras partes del país. Su comportamiento y desenlace está relacionado con la presencia o ausencia de alteraciones genéticas específicas y no específicas.


Abstract: Background: Childhood acute leukemia cytological features are unknown in Chiapas, Mexico. Defining these features is important because this is a relatively isolated population with high consanguinity index, and these aspects could determine differences in responses to treatment and outcome. Methods: Eighty-one childhood acute leukemia cases treated at the Hospital de Especialidades Pediátricas in Chiapas were characterized by morphology, immunophenotype, genotype, initial risk assignment and status at the time of the study. Results: The proportion of leukemic cell types found in this study was B cell, 75.3%; myeloid, 16%; T cell, 3.7% and NK 1.2%. In B cell leukemia, genetic alterations were present in 40.6% of cases and had a specific outcome regardless of initial risk assessment. Cases with MLL gene alteration died within a month from diagnosis. Translocations were present in 17.5% B cases; t(1;19) was present in those with a favorable outcome. The t(12;21) translocation was related to initial remission and midterm relapse and dead. Hyperdiploidy was present in 20% of B cell cases with good outcome. In 38.5%of myeloid cases were translocations and karyotypic abnormalities. Short-term outcome in this group has been poor; 69% have died or abandoned treatment in relapse from 15 days to 37 months after diagnosis. Conclusions: Relative frequency of different types of acute leukemia in patients treated at a tertiary level pediatric hospital in Chiapas, Mexico, was similar to the one found in other parts of the country. Patients' outcome, under a standardized treatment, differs according to the group, the subgroup and the presence and type of genetic alterations.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Translocation, Genetic , Leukemia, Myeloid, Acute/pathology , Diploidy , Recurrence , Time Factors , Remission Induction , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/therapy , Immunophenotyping , Risk Assessment , Genotype , Hospitals, Pediatric , Mexico
8.
J. bras. nefrol ; 38(4): 455-461, Oct.-Dec. 2016. graf
Article in English | LILACS | ID: biblio-829076

ABSTRACT

Abstract The incidence of malignancy is greater in kidney transplant recipients compared to the general population, though the higher risk is not equally distributed to all types of cancers. In face of the increased longevity of renal transplant recipients, certain cancers, such as acute leukemias, are becoming more prevalent. Acute myeloid leukemia (AML) typically presents with cytopenias and infections, both common findings after kidney transplantation. Therefore, the diagnosis of AML may be initially overlooked in these patients. We report the case of a 33-year-old man who presented with fever, pancytopenia and acute worsening of his renal allograft function 9 years after a living unrelated kidney transplant. After initial negative infectious work-up, a kidney biopsy revealed C4d-positive antibody-mediated rejection in combination with scattered atypical inflammatory cells. A subsequent bone marrow biopsy confirmed AML. He underwent successful induction chemotherapy with daunorubucin and cytarabine and ultimately achieved a complete remission. However, he developed a Page kidney with worsening renal function and abdominal pain three weeks after biopsy in the setting of chemotherapy-induced thrombocytopenia. Herein, we discuss the prevalence, risk factors, presentation and management of leukemia after kidney transplantation.


Resumo A incidência de cancer é maior em receptores de transplante renal em comparação com a população em geral, entretanto, o maior risco não é igualmente distribuído em todos os tipos de canceres. Em face do aumento da longevidade de pacientes transplantados renais, certos canceres, tais como leucemias agudas, são cada vez mais prevalentes. Leucemia mielóide aguda (LMA) normalmente se apresenta com citopenias e infecções, quadro comum após o transplante renal. Portanto, o diagnóstico da LMA pode ser inicialmente negligenciado nestes pacientes. Relatamos o caso de um homem de 33 anos de idade que se apresentou com febre, pancitopenia e agravamento agudo da função do enxerto renal de 9 anos após transplante de rim de doador vivo. Após inicial testes negativos para infecção, uma biópsia renal revelou rejeição por anticorpos com C4d positivo e dispersas células inflamatórias atípicas. A subsequente biópsia de medula óssea confirmou LMA. A quimioterapia de indução foi bem-sucedida com daunorubucin e citarabina e, finalmente, obtida uma complete remissão. No entanto, ele desenvolveu uma "Page kidney" com piora da função renal e dor abdominal, três semanas após a biópsia no contexto da trombocitopenia induzida pela quimioterapia. Aqui, discutimos a prevalência, fatores de risco, apresentação e manejo da leucemia pós-transplant renal.


Subject(s)
Humans , Male , Adult , Postoperative Complications/pathology , Leukemia, Myeloid, Acute/pathology , Kidney Transplantation
9.
Article in English | WPRIM | ID: wpr-36803

ABSTRACT

The genetic variant rs16754 of Wilms tumor gene 1 (WT1) has recently been described as an independent prognostic factor in AML patients. It is of great interest to test whether WT1 single nucleotide polymorphism can be used as a molecular marker in other types of cancer, to improve risk and treatment stratification. We performed sequencing analysis of exons 7 and 9 of WT1, which are known mutational hotspots, in a total of 73 patients with BCR-ABL1-negative myeloproliferative neoplasm (MPN) and 93 healthy controls. No previously reported WT1 mutations were identified in the present study. In Korean patients with BCR-ABL1-negative MPN, WT1 genetic variant rs16754 had no significant impact on clinical outcomes. We observed a significant difference in the allelic frequencies of WT1 rs16754 in Koreans between BCR-ABL1-negative MPN cases and healthy controls. Individuals carrying variant G alleles of WT1 rs16754 showed a relatively low prevalence of BCR-ABL1-negative MPN, compared with those carrying wild A alleles of WT1 rs16754 (Hazard ratio 0.10-0.65, P<0.05). Therefore, possession of the variant G allele of WT1 rs16754 may reduce the risk of developing BCR-ABL1-negative MPN.


Subject(s)
Adult , Aged , Aged, 80 and over , Alleles , Asians/genetics , Case-Control Studies , Exons , Female , Fusion Proteins, bcr-abl/genetics , Gene Frequency , Genotype , Humans , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Myeloproliferative Disorders/genetics , Polymorphism, Single Nucleotide , Prognosis , Proportional Hazards Models , Republic of Korea , Risk , Sequence Analysis, DNA , WT1 Proteins/genetics , Young Adult
10.
An. bras. dermatol ; 89(4): 632-637, Jul-Aug/2014. tab, graf
Article in English | LILACS | ID: lil-715521

ABSTRACT

The graft-versus-host disease is the major cause of morbidity and mortality in patients who have undergone hematopoietic stem cell transplantation. Aiming at contributing to the understanding of the role of myeloid and plasmacytoid dendritic cells, and natural killer cells in chronic graft-versus-host disease, we examined biopsies of jugal mucosa of 26 patients with acute myeloid leukemia who had undergone allogenic hematopoietic stem cell transplantation. Half of these patients developed oral chronic graft-versus-host disease. Microscopic sections were immunohistochemically stained for anti-CD1a, anti-CD123 and anti-CD56. We calculated the number of immunostained cells in the corium per square millimeter and applied the Mann-Whitney test. Results showed a statistically significant increase of myeloid dendritic cells (CD1a+; p=0,02) and natural killer cells (CD56; p=0,04) in patients with oral chronic graft-versus-host disease. CD123 immunostaining showed no statistical difference between groups. It was concluded that myeloid dendritic cells and natural killer cells participate in the development of oral chronic graft-versus-host disease.


Subject(s)
Female , Humans , Male , Young Adult , Dendritic Cells/pathology , Graft vs Host Disease/pathology , Hematopoietic Stem Cell Transplantation , Killer Cells, Natural/pathology , Mouth Mucosa/pathology , Apoptosis , Antigens, CD/immunology , Biopsy , Cell Count , Chronic Disease , Dendritic Cells/immunology , Graft vs Host Disease/immunology , Immunohistochemistry , Killer Cells, Natural/immunology , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/pathology , Mouth Mucosa/immunology , Statistics, Nonparametric
11.
Einstein (Säo Paulo) ; 12(1): 109-111, Jan-Mar/2014. graf
Article in English | LILACS | ID: lil-705808

ABSTRACT

A 23-year-old male with a history of bone marrow transplant for acute myeloid leukemia. He presented a large mass in the right inguinal region 5 years ago. Upon physical examination, right-sided cryptorchidism was observed. The tumor markers alpha-fetoprotein and beta-HCG were within normalcy range and lactate dehydrogenase was raised. Computed tomography of the abdomen and pelvis revealed right testicular mass in contiguity with the inguinal canal to the ipsilateral retroperitoneum, associated with right hydronephrosis. Due to the risk of germ-cell tumor in undescended testicle, the patient underwent radical right orchiectomy. The pathological examination showed recurrence of acute myeloid leukemia in the testis. He was referred to oncology for adjuvant therapy. Our literature review found no similar cases described.


Paciente de 23 anos, masculino, com antecedente de transplante de medula óssea por leucemia mieloide aguda. Há 5 anos, apresentou volumosa massa em região inguinal direita. No exame físico, foi constatada criptorquidia à direita. Os marcadores tumorais alfa-fetoproteína e beta-HCG encontravam-se dentro da normalidade, e a desidrogenase láctica estava aumentada. A tomografia computadorizada de abdomen e pelve revelou massa testicular direita com contiguidade pelo canal inguinal, até o retroperitônio ipsilateral, associada a hidronefrose direita. Devido ao alto risco de neoplasia germinativa em testículo criptorquídico, o paciente foi submetido à orquiectomia radical direita, cujo anatomopatológico revelou recidiva de leucemia mieloide aguda em testículo. Foi encaminhado para oncologia para terapia adjuvante. Nossa revisão não revelou nenhum caso semelhante na literatura.


Subject(s)
Humans , Male , Young Adult , Cryptorchidism/surgery , Leukemia, Myeloid, Acute/surgery , Neoplasm Recurrence, Local/surgery , Orchiectomy/methods , Testicular Neoplasms/surgery , Biopsy , Bone Marrow Transplantation , Cryptorchidism/pathology , Leukemia, Myeloid, Acute/pathology , Neoplasm Recurrence, Local/pathology , Tomography, X-Ray Computed , Treatment Outcome , Testicular Neoplasms/pathology
12.
Indian J Cancer ; 2013 Apr-June; 50(2): 154-158
Article in English | IMSEAR | ID: sea-148641

ABSTRACT

Acute myeloid leukemia (AML) in older adults differs biologically and clinically from that in younger patients and is characterized by adverse chromosomal abnormalities, stronger intrinsic resistance, and lower tolerance to chemotherapy. In patients over age 60 with AML, cure rates are under 10% despite intensive chemotherapy, and most of them die within a year of diagnosis. Over the last decade, metronomic chemotherapy has emerged as a potential strategy to control advanced/ refractory cancer. Here, we report a case of a 68‑year‑old gentleman having AML with high‑risk cytogenetic features, who achieved complete remission on our oral metronomic PrET (PrET: Prednisolone, etoposide, thioguanine) protocol on an outpatient basis. He was later treated with standard high‑dose (HD) cytosine arabinoside (Ara‑C) consolidation followed by maintenance with etoposide, thioguanine, and sodium valproate. Presently, the patient is nearly 35 months since diagnosis and 21 months off treatment. This case report and review highlights that the combination of oral low‑intensity metronomic therapy, followed by standard HD consolidation therapy and metronomic maintenance therapy may be well tolerated by elderly patients especially with less proliferative, high (cytogenetic)‑risk AML who are otherwise deemed to be unfit for intensive intravenous induction chemotherapy regimens. References for this review were identified through searches of Pubmed for recent publications on the subject as well as searches of the files of the authors themselves. The final list was generated on the basis of originality and relevance to this review.


Subject(s)
Administration, Metronomic , Aged , Cytarabine/administration & dosage , Disease-Free Survival , Etoposide/administration & dosage , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/pathology , Male , Prognosis , PubMed , Remission Induction
13.
Rev. obstet. ginecol. Venezuela ; 73(1): 65-71, mar. 2013. ilus
Article in Spanish | LILACS | ID: lil-690985

ABSTRACT

Se trata de primigesta de 18 años, etnia wayuu, con amenorrea de 30,5 semanas, quien acude en condiciones clínicas de cuidado por presentar disnea acentuada desde hace una semana. El examen físico demostraba palidez cutánea marcada, hiperplasia gingival, soplo holosistólico grado I, taquisfigmia, murmullo vesicular abolido en ambas bases pulmonares con crepitantes bilaterales, abdomen globoso, útero grávido, AU: 27 cm, feto cefálico activo, tacto sin modificaciones. Presenta anemia, marcada leucocitosis, hipoproteinemia, elevación de LDH, y patrón de consolidación bibasal en radiografía pulmonar. Ingresa con diagnóstico de embarazo simple pretérmino, neumonía bilateral, enfermedad linfoproliferativa, y sepsis (?); durante su evolución presenta alteración en el perfil biofísico fetal y hemodinámico, practicándose cesárea segmentaria debido a oligoamnios y sufrimiento fetal agudo. Se obtiene neonato pretérmino, el cual ingresa por prematuridad, sepsis neonatal y enfermedad de membrana hialina. Frotis de sangre periférica revela leucopenia con predominio de monocitos, trombocitopenia, anisocitosis, hipocromia, y macroplaquetas; mientras que el aspirado de médula ósea presentaba 80 % de infiltración de mieloblastos y alteraciones en la citometría de flujo. Recibe quimioterapia según protocolo BMS y manejo médico de las complicaciones presentadas, fallece durante el puerperio tardío.


Primigravida 18 years, ethnicity Wayuu, with 30.5 weeks of amenorrhea, who went into clinical conditions of care for presenting accentuated dyspnea since a week ago. Physical examination showed marked skin pallor, gingival hyperplasia, holosystolic blow, palpitations, vesicular murmur abolished in lung’s bases with bilateral crackles. Abdomen with graves uterus, height 27cm, and cephalic active fetus; vaginal touch unchanged. Presents anemia, marked leukocytosis, hypoproteinaemia, elevated LDH, and pattern of consolidation at lung’s radiographers. She is admitting with diagnosed of preterm pregnancy, bilateral pneumonia, lymphoproliferative disease, and sepsis (?); during its evolution presents impaired fetal biophysical profile and hemodynamic, practised caesarean operation due to oligoamnios and acute fetal distress. Obtained preterm infant, who was admitted because of prematurity, neonatal sepsis and hyaline membrane disease. Peripheral blood smear reveals predominantly monocytes leukopenia, thrombocytopenia, anisocitosis, hipocromia and macroplaquets. While the bone marrow aspirate showed 80 % of infiltration mieloblasts cells and alterations in the cytometry of flow. Receives chemotherapy by protocol BMS and medical management of complications presented, dies during the late puerperium.


Subject(s)
Humans , Female , Pregnancy , Adolescent , Pregnancy Complications, Neoplastic/pathology , Leukemia, Myeloid, Acute/pathology , Pregnancy Complications, Neoplastic/blood , Fatal Outcome , Leukemia, Myeloid, Acute/blood , Rare Diseases
14.
Article in English | WPRIM | ID: wpr-148465

ABSTRACT

The risk of osteoporosis or osteopenia is known to increase after childhood cancer treatment. The purpose of this study was to evaluate patterns of bone mineral density (BMD) and to identify factors related to the decreased BMD in childhood cancer survivors. We studied 78 patients (34 boys, 44 girls) treated for childhood cancer. Twenty (25.7%) patients had lumbar BMD (LBMD) standard deviation score (SDS) lower than -2. Nineteen (24.4%) patients had femur neck BMD (FNBMD) SDS lower than -2. The patients treated with hematopoietic stem cell transplantation had lower LBMD SDS (-1.17 +/- 1.39 vs -0.43 +/- 1.33, P = 0.025). The risk of having LBMD SDS < -2 was higher in the patients treated with glucocorticoid (GC) for graft-versus-host disease (GVHD) (36.6% vs 13.5%; odds ratio [OR], 3.7; P = 0.020). In multivariate logistic regression analysis, longer duration of GC treatment for GVHD (OR, 1.12; 95% confidence interval [CI], 1.05-1.20) and lower body mass index (BMI) SDS (OR, 0.59; 95% CI, 0.36-0.95) were associated with decreased LBMD SDS. These findings suggest that prolonged GC use and reduction in BMI are risk factors for decreased BMD in childhood cancer survivors. Anticipatory follow-up and appropriate treatment are necessary, especially for the patients with risk factors.


Subject(s)
Adolescent , Body Mass Index , Bone Density/drug effects , Bone Diseases, Metabolic/chemically induced , Child , Female , Glucocorticoids/adverse effects , Graft vs Host Disease/drug therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Hormones/blood , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Leukemia, Myeloid, Acute/pathology , Male , Osteoporosis/chemically induced , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Risk Factors , Survivors
15.
Braz. j. med. biol. res ; 44(7): 660-665, July 2011. ilus, tab
Article in English | LILACS | ID: lil-595706

ABSTRACT

We evaluated the outcome of 227 patients with acute myeloid leukemia during three decades (period 1 - 1980’s, N = 89; period 2 - 1990’s, N = 73; period 3 - 2000’s, N = 65) at a single institution. Major differences between the three groups included a higher median age, rates of multilineage dysplasia and co-morbidities, and a lower rate of clinical manifestations of advanced leukemia in recent years. The proportion of patients who received induction remission chemotherapy was 66, 75, and 85 percent for periods 1, 2, and 3, respectively (P = 0.04). The median survival was 40, 77, and 112 days, and the 5-year overall survival was 7, 13, and 22 percent, respectively (P = 0.01). The median disease-free survival was 266, 278, and 386 days (P = 0.049). Survival expectation for patients with acute myeloid leukemia has substantially improved during this 30-year period, due to a combination of lower tumor burden and a more efficient use of chemotherapy and supportive care.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Young Adult , Hospitalization/statistics & numerical data , Leukemia, Myeloid, Acute/therapy , Brazil/epidemiology , Disease-Free Survival , Induction Chemotherapy/methods , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/pathology , Prognosis , Retrospective Studies , Survival Rate , Treatment Outcome
17.
Int. j. morphol ; 29(1): 151-157, Mar. 2011. ilus
Article in Spanish | LILACS | ID: lil-591967

ABSTRACT

Existe creciente evidencia que apoya la presencia de un perfil de metilación específico para Leucemia Mieloide Aguda (LMA). La metilación de los islotes CpG en las regiones promotoras de los genes supresores de tumores es un importante mecanismo de control epigenético y participa en el silenciamiento transcripcional. Esto puede contribuir a un nuevo entendimiento de la biología de la enfermedad y vislumbrar nuevas oportunidades terapéuticas. Identificar el perfil de metilación de las áreas promotoras de un grupo de genes supresores de tumores; (p15, p16, ESR1, IGSF4, SOCS1, RARB y DAPK), y relacionar el estatus de metilación gen especifica o combinada con diferentes parámetros clínico patológicos. Se utilizaron muestras de sangre o médula ósea obtenidas al momento del diagnóstico de 33 pacientes con LMA, infantil y del adulto, recolectadas entre los años 1997 y 2008 en el Hospital Hernán Henríquez de Temuco. Se evaluó la presencia de hipermetilación mediante una Reacción de Polimerasa en Cadena Metilación Específica (MSP), previa modificación con bisulfito de sodio. La frecuencia de metilación de los pacientes estudiados fue de 88 por ciento, 27 por ciento, 27 por ciento, 21 por ciento, 15 por ciento, 3 por ciento y 0 por ciento para ESR1, RARb, IGSF4, p15, SOCS1, DAPK, y P16, respectivamente. La hipermetilación de P15 y RARb presentó una asociación significativa para una menor supervivencia en forma individual (p=0,03 y p=0,02), y combinada (p=0,002). No se encontraron diferencias significativas entre metilación y los otros parámetros clínicos analizados. Los pacientes con LMA presentan hipermetilación de la región promotora en algunos genes supresores de tumores, afectando negativamente la supervivencia. Esto pudiese eventualmente contribuir al establecimiento de un patrón de metilación determinado con utilidad clínica.


There is growing evidence than acute myeloid leukemia presents a specific methylation profile. The Methylation of CpG islands within gene promoters is a major epigenetic transcriptional control mechanism and plays a critical role in the transcriptional silencing of tumor suppressor genes. This provides new insights into the biology of the disease and it may offer novel therapeutic opportunities. To identify the promoter methylation profile of tumor suppressor genes (p15, p16, ESR1, IGSF4, SOCS1, RARB y DAPK), and to relate the percentage of methylation with clinicopathological features, as age, gender, white cell count, disease classification and survival rates. Bone marrow and peripheral blood samples were collected at diagnosis from 33 patients with acute myeloid leukemia, infants and adult, between 1997 and 2008 from Hernán Henríquez Aravena Hospital, Temuco, Chile. Methylation in the promoter areas of each tumor suppressor gene was analyzed using the mehylation specific polymerase chain reaction (MSP) technique using sodium bisulfite modification. The frequency of hypermethylation among the patient samples was 88 percent, 27 percent, 27 percent, 21 percent, 15 percent, 3 percent and 0 percent for ESR1, RARb, IGSF4, p15, SOCS1, DAPK, and P16 for each one. Methylation was significantly associated with an inferior overall survival (p=0.03 and p=0.02). When both genes are used, inferior survival is even more significant (p=0.002). There is no significant correlation between methylation and clinicopathological features.Patients with AML have hipermetilation at the promoter region of some tumor supressor genes, with a negative effect in the overall survival. This could eventually become part of establishing a characteristical methilation pattern with clinical utility.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Genes, Tumor Suppressor/physiology , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/pathology , Leukemia, Myeloid, Acute/blood , Epigenesis, Genetic/physiology , Epigenesis, Genetic/genetics , DNA Methylation
18.
AJM-Alexandria Journal of Medicine. 2011; 47 (3): 225-235
in English | IMEMR | ID: emr-145337

ABSTRACT

Nucleophosmin/B23 [NPM] is a 38 kDa molecular phosphoprotein involved in ribosome assembly and transport. Findings have revealed a complex scenario of NPM functions and interactions, pointing to proliferative and growth-suppressive roles. NPM appears to be more abundant in tumour cells than in normal cells. The aim of the work was to identify cytoplasmic localization of NPM using bone marrow clot biopsy and correlate it with disease and patient characteristics and the known prognostic factors, induction chemotherapy response and survival after 12 months of follow up. The present work was undertaken on 50 cases of normal karyotype acute myeloid leukaemia classified according to modified FAB system. Bone marrow aspirates were obtained, clotted and a formalin-fixed, paraffin embedded cell block was prepared. Sections were immunostained for NPM. Twenty-six cases [52%] had cytoplasmic positivity [cNPM+] while the remaining 24 cases [48%] had nuclear restricted NPM [cNPM]. cNPM positivity was significantly variable among the different FAB subtypes being the most prevalent among M5 and M2 cases, was associated with high blast and white blood cell count at diagnosis. It was significantly correlated with CD34 negativity, CD14 positivity but not with FLT3 mutations. Clinically no relation between cNPM positivity and age, sex nor extramedullary involvement of the studied patients was proven. The cytoplasmic positivity for NPM was significantly correlated with increased survival and better outcome after cycles of chemotherapy. So it can be regarded as a good prognostic marker. FLT3 positivity affected the survival of the cNPM negative group of patients remarkably, denoting the importance of combining both their statuses to predict outcome of therapy and survival. Our data confirm that cytoplasmic NPM1 immunoreactivity is predictive of NPM1 mutations and can be included in the routine diagnostic and prognostic workup of AML


Subject(s)
Humans , Female , Male , Nuclear Proteins/blood , Follow-Up Studies , Leukemia, Myeloid, Acute/pathology , Immunohistochemistry , Survival Rate
20.
Article in Korean | WPRIM | ID: wpr-164245

ABSTRACT

BACKGROUND: The bone marrow (BM) cellularity has been used as a major index for the evaluation of hematologic diseases and malignancies. However, the microscopic evaluation lacks objectivity because of considerable variations among different observers. We measured myelocrit cellularity as an objective method to evaluate the cellularity. METHODS: Between November 2007 and January 2008, 489 consecutive BM aspirates including 25 cases of AML D7 marrow (7 days after initiation of chemotherapy) were examined. The conventional BM cellularity was evaluated using BM needle biopsies after hematoxylin-eosin stain. EDTA-anticoagulated BM aspirates were put into the Wintrobe tubes, centrifuged and the thickness of 5 layers from the bottom was measured: RBC, buffy coat (BC), plasma, BM particle, and fat layers. The myelocrit cellularity was defined as the ratio of BC to the BC plus fat layers. RESULTS: Both of the thickness of BC layer (r=0.721, P=0.000) and the myelocrit cellularity (r=0.735, P=0.000) correlated well with the conventional cellularity. However, the AML D7 BM cellularity correlated with BC layer (r=0.589, P=0.002), but not with the myelocrit cellularity (r=0.281, P=0.231). The cellularity of the BM other than AML D7 marrow showed a better correlation with the myelocrit cellularity (r=0.826, P=0.000) than the BC layer (r=0.713, P=0.000). CONCLUSIONS: The myelocrit is a simple, reproducible and objective method to determine the BM cellularity. For accurate assessment of BM cellularity, measurement of the thickness of BC layer in AML D7 BM and of the myelocrit cellularity in other BM samples has better be used.


Subject(s)
Adolescent , Adult , Aged , Bone Marrow/pathology , Cell Separation/instrumentation , Child , Child, Preschool , Female , Humans , Infant , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL